Tetrahydroisoquinoline Antimalarials for Single-Dose Cure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimalarial drugs face challenges such as high treatment adherence issues, emerging resistance, and the need for single-dose treatments to improve compliance and efficacy, particularly against Plasmodium falciparum.
Innovation Solution
Development of novel tetrahydroisoquinoline derivatives with improved metabolic stability, allowing for a significantly lower efficacious dose and reduced pill burden, potentially achieving parasitological cure with a single dose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If artemisinin-based combination therapies are administered over three days, then high efficacy against Plasmodium falciparum is achieved, but treatment adherence becomes difficult and effectiveness is reduced
Solution Approach 1:
The patent segments the multi-day treatment regimen into a single-dose formulation by developing novel tetrahydroisoquinoline derivatives with extended half-life and sustained antimalarial activity, eliminating the need for multiple doses while maintaining efficacy
Solution Approach 2:
The patent applies preliminary action by designing compounds with optimized pharmacokinetic properties that maintain therapeutic levels throughout the treatment period, pre-establishing sustained drug presence in the body to cover the full treatment duration with a single administration
2Reliability
If higher doses are administered to ensure parasitological cure, then treatment efficacy is improved, but pill burden and treatment complexity increase
Solution Approach 1:
The patent merges multiple treatment functions into a single compound molecule with dual activity against both asexual and gametocyte stages of Plasmodium, achieving comprehensive parasitological cure with one pill rather than multiple separate medications
Solution Approach 2:
The novel tetrahydroisoquinoline derivatives exhibit universal antimalarial activity across multiple parasite stages and species, providing broad-spectrum coverage and ensuring cure regardless of specific Plasmodium type with a single dose
3Ease of manufacture
If existing antimalarial drugs are used, then treatment is available, but metabolic stability is insufficient leading to higher required doses
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of isoquinoline derivatives to optimize metabolic stability through specific substitutions and functional groups, increasing half-life and reducing clearance rates to achieve sustained therapeutic effects at lower doses
Data Source
AI summary
The present invention is related to new derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to dihydroisoquinoline derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.